Workflow
陕西新首富!夫妻卖面膜,身家超400亿
Sou Hu Cai Jing·2025-05-14 12:58

Core Viewpoint - The company, Juzhi Biotechnology, has experienced significant growth since its establishment, with its market capitalization surpassing that of its competitor, Proya, and reaching 88.8 billion HKD (approximately 81.9 billion RMB) in 2025, making it the highest-valued domestic beauty brand in China [1][4]. Financial Performance - In 2024, Juzhi Biotechnology reported revenue of 5.539 billion RMB, a year-on-year increase of 57.2%, and a net profit of 2.062 billion RMB, up 54.3%, with a gross margin of 82.1% [6][13]. - The company's flagship brand, Kefu Mei, generated 4.541 billion RMB in revenue, accounting for 82% of total revenue, and saw a growth of 62.9% [10][13]. Market Position and Strategy - Juzhi Biotechnology has established a strong market presence by focusing on collagen products, with 80% of its revenue derived from collagen-based products [6][10]. - The company has a dual sales strategy targeting both medical institutions and general consumers, which has contributed to its rapid revenue growth [12]. - Juzhi Biotechnology holds 167 patents and has developed a unique position in the market by not selling raw materials or licensing technology, thus maintaining pricing power [17][18]. Industry Trends - The market for recombinant collagen in China has grown significantly, with projections indicating a rise from 15 billion RMB in 2017 to 1,083 billion RMB by 2027, reflecting a compound annual growth rate of 42.4% [14]. - The company faces increasing competition as more players enter the high-margin medical beauty sector, which could impact its market dominance [20][23]. Challenges and Risks - Despite its current success, Juzhi Biotechnology's high gross margin of 82% is under pressure due to rising product costs and increased competition in the collagen market [20]. - The company has seen a decline in its gross margin from 83.6% in 2023, indicating potential challenges in maintaining profitability amidst market changes [20]. - Juzhi Biotechnology's research and development spending is relatively low compared to competitors, which may hinder its ability to innovate and maintain a competitive edge [21].